EUCTR2004-000299-15-GB进行中（未招募）1 期
A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients. - Not applicable
Algeta ASA, Oslo, Norway0 个研究点目标入组 0 人开始时间: 2005年4月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1)Histologically/cytologically confirmed adenocarcinoma of the prostate
- •2)Patient is hormone refractory with evidence of progressive disease:
- •Patient must be maintained on androgen ablation therapy with LHRH agonist or have undergone orchiectomy
- •Patient’s testosterone level is required to be equal to or below 50 ng/dl
- •Patients in which flutamide, nilutamide, megestrol acetate, polyestradiolphosphate, aminoglutethimide, and ketoconazole, has been recently withdrawn must demonstrate progression of disease and be at last 4 weeks beyond the discontinuation of such agents; for bicalutamide 6 weeks is required
- •Increase in PSA levels in two consecutive measurements with at least one week apart, demonstrating an increase over the reference (nadir) value, and with the final PSA ??5 ng/ml
- •oA reference PSA (nadir) value must be measured at least 4 weeks after the discontinuation of flutamide, nilutamide, megestrol acetate, polyestradiolphosphate, aminoglutethimide, and ketoconazole, and at least 6 weeks after discontinuation of bicalutamide
- •oIf the third PSA value is lower than the second value, the patient could still be eligible, provided a fourth measurement obtained at least 1 week after the third PSA value, is grater than the second PSA value and ??5 ng/ml
- •3)Multifocal (>1) skeletal metastases confirmed by scintigraphy within the last 6 weeks
- •4)Bone pain with a score of at least 2 on BPI average pain, despite adequate use of analgesics, that correlates with areas of increased uptake (osteoblastic activity) on bone scintigraphy
- •5)Performance status: ECOG 0-2 or Karnofsky ??60%
- •6)Life expectancy: At least 3 months
- •7)Age: more than 40 years
- •8)Laboratory requirements:
- •a.Neutrophil count ??1,5 x 109/L
- •b.Platelet count ??100 x109/L
- •c.Hemoglobin > 95 g/L
- •d.Bilirubin within normal institutional limits
- •e.ASAT and ALAT <2,5 times upper limit of normal (ULN)
- •9)The patient is willing and able to comply with the protocol (including maintenance of patient diary and completion of pain assessment forms), and agrees to return to the hospital for follow-up visits and examinations
- •10)The patient has been fully informed about the study and has signed the informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Has received an investigational drug within 4 weeks before the administration of radium-223, or is scheduled to receiving one during the study period
- •2)Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- •3)Has received prior hemibody external radiotherapy
- •4)Has received systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium 188 for the treatment of bony metastases within the last year prior to inclusion
- •5)Has started treatment with bisphosphonates less than 3 months prior to administration of study drug
- •6)Patients experiencing hormone withdrawal syndrome, or are ??4 weeks post withdrawal of antiandrogen therapy (6 weeks for bicalutamide)
- •7)Patient who have started steroids or changed to treatment with steroids within the last 4 weeks prior to administration of radium-223
- •8)Has other clinically significant or symptomatic disease, which might interfere with the assessment of bone pain, e.g. spinal cord compression, compression or infiltration of a neural plexus, nerve root or peripheral nerves
- •9)Other currently active (relapse within the last 3 year) malignancy (except nonmelanoma skin cancer), or known brain or visceral metastases dominating the clinical picture of the patient
- •10)Other serious illness or medical condition:
- •any uncontrolled infection
- •cardiac failure Classification III or IV (New York Heart Association)
- •Crohn disease or Ulcerative colitis
- •known bone fracture within 8 weeks
研究者
相似试验
进行中（未招募）
1 期
A trial to determine the how safe and effective the test drug is for obese males with hypogonadotropic hypogonadism. The trial is blinded and the subjects may be given the test drug or a placebo.Hypogonadotropic hypogonadism (HH)MedDRA version: 20.0Level: LLTClassification code 10021012Term: Hypogonadotrophic hypogonadismSystem Organ Class: 100000004860EUCTR2015-005760-42-GBMereo BioPharma 2 Limited268
进行中（未招募）
1 期
A trial to determine the how safe and effective the test drug is for obesemales with hypogonadotropic hypogonadism. The trial is blinded and thesubjects may be given the test drug or a placebo.Hypogonadotropic hypogonadism (HH)MedDRA version: 20.0Level: LLTClassification code 10021012Term: Hypogonadotrophic hypogonadismSystem Organ Class: 100000004860EUCTR2015-005760-42-ITMEREO BIOPHARMA GROUP LTD271
进行中（未招募）
1 期
A trial to determine the how safe and effective the test drug is for obese males with hypogonadotropic hypogonadism. The trial is blinded and the subjects may be given the test drug or a placebo.EUCTR2015-005760-42-ESMereo BioPharma 2 Limited268
进行中（未招募）
1 期
A double-blind, dose-response, phase II, multicentre study of radium-223 (Alpharadin TM ) for the palliation of painful bone metastases in hormone refractory prostate cancer patientsThe target population is patients suffering from bone pain due to skeletal metastasis secondary to prostate cancer.EUCTR2004-000299-15-SEAlgeta AS
进行中（未招募）
1 期
Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary DiseaseEUCTR2012-004949-32-DETheravance, Inc.62